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Abstract
Introduction: The objective of the present study was to examine the association of baseline demographic and
clinical characteristics with sequentially obtained measurements of forced vital capacity (FVC), expressed as a
percentage of the predicted value, and to identify predictors of the decline rate in FVC over time in the Genetics
versus Environment in Scleroderma Outcome Study (GENISOS).
Methods: To date, 266 patients have been enrolled in GENISOS, a prospective, observational cohort of patients
with early systemic sclerosis. In addition to pulmonary function tests (PFTs), clinical and laboratory data were
obtained from each patient. We analyzed 926 FVC measurements utilizing generalized linear mixed models. The
predictive significance of baseline variables for the decline rate in FVC was investigated by the interaction term
between the variable and the follow-up time within the first 3 years after enrollment as well as throughout the
entire follow-up time.
Results: The cohort consisted of 125 white, 54 African American, and 77 Hispanic patients with average disease
duration of 2.5 years at enrollment. The mean follow-up time was 3.8 years, ranging up to 11.4 years. A number of
baseline variables, including antibody status, African American ethnicity, disease type, baseline PFT values, modified
Rodnan Skin Score, fibrosis on chest radiograph, and lung and skin subscores of the Severity Index, were associated
with serially measured FVC levels. However, only the presence of anti-topoisomerase I antibodies (ATA) was
associated with lower FVC levels (P < 0.001) as well as accelerated decline rate in FVC within the first 3 years of
follow-up (P = 0.02). None of the baseline variables predicted the rate of decline in FVC on long-term follow-up.
Patients with rapidly progressive ILD, however, were under-represented in the long-term follow-up group because
the accelerated rate of decline in FVC was associated with poor survival (P = 0.001).
Conclusions: Presence of ATA was the only baseline variable associated with differential FVC levels, predicting the
rate of decline in FVC within the first 3 years of follow-up. The association of faster decline in FVC with poor
survival further emphasizes the need for identification of predictive biomarkers by collection of genetic information
and serial blood samples in cohort studies.
Introduction
Systemic sclerosis (SSc) is associated with substantial
morbidity and mortality [1,2], and leads to detrimental
effects on health-related quality of life [3]. Pulmonary
involvement, including both interstitial lung disease
(ILD) and pulmonary arterial hypertension, has become
the primary cause of SSc-related death [4]. Although a
variety of pulmonary function test (PFT) measures have
long been used to study ILD in SSc, only the forced
vital capacity (FVC) has been validated as an outcome
measure in randomized controlled trials [5]. Further-
more, the Genetics versus Environment in Scleroderma
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vations [6,7] that FVC <50% at baseline was highly pre-
dictive of mortality in SSc [2].
Sequential measurements of pulmonary function in
patients with SSc have shown remarkable variability in
the progression of restrictive lung disease, ranging from
an indolent course with stable PFT values to a rapidly
progressive disease leading to respiratory failure and
eventually death [7-10]. Anti-topoisomerase I antibodies
(ATA) and the absence of anti-centromere antibodies
(ACA) are associated with the presence of ILD at baseline
[11-15]. However, the data on their predictive role for the
decline in FVC percentage predicted over time are con-
flicting. While ACA and ATA were not predictive of the
FVC decline rate in some studies [7,14,16], ATA and dif-
fuse cutaneous SSc were predictive of the FVC decline
rate in the univariate analysis in one study; however, only
diffuse cutaneous involvement was predictive of a
decrease in FVC in the multivariate analysis in this study
[17]. Similarly, other demographic and clinical features
associated with ILD at the baseline visit - such as male
sex [7], African American ethnicity [7,15] and cardiac
involvement [7,18] - did not predict the rate of decline in
percentage predicted FVC [7,16,17,19-21]. Studies inves-
tigating the predictive significance of baseline percentage
predicted FVC have reported inconsistent results. Low
baseline FVC was associated with an accelerated decline
in pulmonary function in some reports [16,22], but not
in other studies [7,9,14,19-21,23].
Discrepant results may be explained by methodologi-
cal differences including retrospective study design
[7,12,14,16,22,23], patient selection for clinical trials
[20,21] and small sample size [8,9,19].
Previously we reported the association of demographic
and clinical characteristics with pulmonary disease at
baseline in the GENISOS cohort. African American eth-
nicity, presence of cardiac involvement, modified Rod-
nan Skin Score [24], serum creatine phosphokinase
levels and absence of ACA were negatively related to
percentage predicted FVC at the baseline visit [18].
The objective of the present prospective study was to
examine the association of baseline variables with
sequentially obtained percentage predicted FVC and to
identify baseline demographic and clinical predictors of
the decline rate in percentage predicted FVC over time.
S u c hap r e d i c t i v em o d e lw o u l db eh i g h l yv a l u a b l eb o t h
in clinical practice and in the design of clinical trials.
Materials and methods
GENISOS was designed to identify factors predictive of
various outcomes in SSc. This prospective cohort study
is a collaborative effort between the University of Texas
Health Science Center at Houston, the University of
Texas Medical Branch at Galveston and the University
of Texas Health Science Center at San Antonio. Recruit-
ment into the study started in 1998. Initial enrollment
and follow-up study visits are ongoing.
Patient selection
Details of patient selection and recruitment have been
previously published by Reveille and colleagues [25].
Patients who fulfilled the following inclusion criteria are
enrolled: age ≥18 years; diagnosis according to the
American College of Rheumatology (formerly the Amer-
ican Rheumatism Association) preliminary classification
criteria for SSc [26]; disease onset within the previous
5 years (defined as the first non-Raynaud’s phenomenon
symptom); and defined ethnicity with all four grandpar-
ents from the same ethnic group. Patients who had SSc-
like illnesses associated with environmental, ingested, or
injected agents were excluded from the study.
All enrolled patients at the time of analysis were
included in the current study. Patients were assigned to
the following four ethnic groups: white, African Ameri-
can, Hispanic and other. A total of 10 patients were
assigned to the other group consisting of one Native
American and nine Asian patients. The study was
approved by the institutional review board of all partici-
pating sites, and written informed consent was obtained
from all study subjects.
Data collection
A standardized clinical manifestation form is completed at
baseline and at follow-up visits [25]. This assessment
includes calculation of the modified Rodnan Skin Score
[24] and a previously validated severity scale, the Medsger
Severity Index [27]. Electrocardiograms, chest radiographs,
and laboratory tests including complete blood count,
metabolic panel, creatine phosphokinase and urinalysis are
also obtained at baseline and annually thereafter. Pulmon-
ary fibrosis on chest radiograph is defined as increased
interstitial markings not explained otherwise. Information
on annual income and educational levels is also collected
and categorized as described in Supplement 1 in Addi-
tional file 1. Furthermore, the following autoantibodies are
determined in the laboratories of the University of Texas
Health Science Center at Houston: anti-nuclear antibodies
and ACA by indirect immunofluorescence utilizing HEp-2
cell substrates (Antibodies Incorporated, Davis, CA, USA);
ATA, anti-Ro, anti-La, anti-Smith antibody, and anti-U1-
ribonucleoprotein by passive immunodiffusion against calf
thymus extract (INOVA Diagnostics, San Diego, CA,
USA); and anti-RNA polymerase III antibodies by ELISA
(MBL, Nagoya, Japan). Anti-fibrillarin antibodies (U3-ribo-
nucleoprotein) are determined on patients with anti-
nucleolar antibodies by immunoprecipitation of the
recombinant protein at the University of Calgary, as
previously described [28].
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first non-Raynaud’s phenomenon symptom in our study.
We also utilized a second method for calculation of the
disease duration, however, in which the disease onset
was defined as the time of first symptom attributable to
SSc (first Raynaud’s phenomenon symptom or non-
Raynaud’s phenomenon symptom).
Chest CT, echocardiogram and right heart catheteriza-
tion are not included as a routine part of the GENISOS
visit, but the results of these studies are captured if
obtained as part of the usual clinical care. Only a small
group of subjects had undergone a chest CT or right
heart catheterization at enrollment, so the results of
these studies were not included in our analysis. A larger
portion of patients (23.68%), however, had undergone
an echocardiogram at enrollment; the predictive signifi-
cance of elevated systolic pulmonary arterial pressure,
defined as a right ventricular systolic pressure >40
mmHg, was therefore investigated in this subgroup of
patients.
We also determined the vital status of each patient as
of November 2009 by review of the National Death
Index and the Social Security Death Database.
Pulmonary function test
PFTs are performed at the three sites on the baseline
visit and annually thereafter. Variables are expressed as
the percentage predicted FVC, forced expiratory volume
in 1 second, total lung capacity, and diffusing capacity
(liters) of carbon monoxide (DLco). The predicted
values are calculated according to the patient’sa g e ,
height, weight, gender and ethnicity utilizing consistent
reference values. The DLco percentage predicted values
are also corrected for the patient’s actual hemoglobin
level [29]. Furthermore, all PFTs are reviewed by a pul-
monologist (RME-Y-M) and studies are excluded that
do not fulfill the American Thoracic Society/European
Respiratory Society criteria for pulmonary function test-
ing [30-32].
Statistical analysis
The generalized linear mixed models were used to eval-
uate the effects of the measured baseline demographic
and clinical variables on the percentage predicted FVC.
First, the association of the baseline variables with serial
measurements of percentage predicted FVC was exam-
ined. Subsequently, predictor-follow-up time interac-
tions were included in the models to evaluate the effects
of the baseline and clinical variables on the change in
percentage predicted FVC over time. Those interactions
evaluated whether a predictor was an effect modifier
(that is, whether the change in percentage predicted
FVC over time depended on the baseline variable). In
other words, a baseline variable was considered a
predictor of decline rate in FVC if the interaction term
between the variable and the follow-up time was signifi-
cant with regard to serial measurements of percentage
predicted FVC.
The identification of predictors was conducted for two
different follow-up periods. First, we limited our analysis
to FVC measurements obtained within 3 years after
enrollment. The cut-off point of 3 years was selected
because this approximated to the average disease dura-
tion of 5 years in our cohort. Next, we analyzed all FVC
measurements throughout the entire follow-up time.
This approach was chosen was chosen to diminish the
effects of survival bias because patients with rapidly
progressive pulmonary disease had higher mortality (see
results) and were less likely to be present in the long-
term follow-up group (up to 11.4 years).
We treated patients as a sample from a larger popula-
tion, and modeled between-patient variability in percen-
tage predicted FVC as a random intercept. We also
modeled between-patient variability in the change in
percentage predicted FVC over time by a random slope
(that is, we estimated a separate slope for each patient).
We accounted for the correlations among random-effect
parameters by an independent covariance matrix.
Exchangeable or unstructured covariance matrices did
not improve model fit evaluated by the Aikaike Informa-
tion Criteria. The relationship between follow-up time
and FVC was appropriately modeled by a linear function
(a second-order polynomial did not improve the model
fit). Generally, mixed-effect models allow inclusion of all
data points in the analysis and can be used when some
data points are missing.
Box-and-whisker plots were used to illustrate the
trend in progression of percentage predicted FVC in the
overall population and subgroups of patients based on
disease type [33] and on disease duration at enrollment.
P < 0.05 was considered significant. Analyses were con-
ducted with Stata 10.1 statistical software (StataCorp LP,
College Station, TX, USA).
Results
Sample characteristics
Between January 1998 and October 2009, 266 patients
were enrolled in the GENISOS cohort. The mean (±
standard deviation) follow-up time was 3.76 (± 3.35)
years, ranging up to 11.39 years. A total of 926 FVC
measurements belonging to 244 patients fulfilled the
American Thoracic Society/European Respiratory
Society criteria and were included in the analysis. Over-
all, 182 patients had at least two FVC measurements
that fulfilled these criteria.
The mean (± standard deviation) age of patients at
enrollment was 48.63 (± 13.5) years; 80.1% of the study
population was female. The cohort consisted of 125
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African American, and 10 (3.8%) subjects with other
ethnic backgrounds. Only 49 patients (18.4%) were cur-
rent smokers at the time of enrollment. Table 1 presents
the demographic characteristics of patients at baseline.
The mean (± standard deviation) disease duration at
enrollment was 2.53 (± 1.63) years; 41.4% of patients
had limited cutaneous disease. ACA, ATA and anti-
RNA polymerase III antibodies were present in 12.1%,
18.4% and 22.9% of patients, respectively. The propor-
tion of patients with a baseline FVC <80% was 41.9%.
Furthermore, only 22 patients (8.3%) had received cyclo-
phosphamide before enrollment or during the follow-up
period. Clinical characteristics of the GENISOS cohort
at enrollment are presented in Table 1 and in Supple-
ment 2 in Additional file 1. Moreover, a detailed com-
parison of baseline demographic and clinical
characteristics between the investigated ethnic groups
has been published previously [18].
Factors associated with percentage predicted FVC
We next examined the association of baseline character-
istics with FVC. For this analysis, we included all avail-
able baseline and follow-up FVC measurements as our
outcome variable and accounted for within-subject corre-
lation. As expected, the follow-up time was associated
with a decline in percentage predicted FVC (P < 0.001).
Furthermore, the following variables were associated with
a lower percentage predicted FVC after adjustment for
follow-up time (Table 2): African American ethnicity in
comparison with white ethnicity (P =0 . 0 0 2 ) ,p r e s e n c eo f
ATA (P < 0.001), higher modified Rodnan Skin Score
(P = 0.001), higher visual analog score for dyspnea
(P < 0.001), presence of basal crackles on physical exami-
nation (P < 0.001), signs of pulmonary fibrosis on chest
radiograph (P < 0.001), and abnormal creatine phospho-
kinase (P = 0.046). While the presence of ACA
(P < 0.001) and limited disease type (P = 0.012) were
each associated with higher percentage predicted FVC.
As expected, higher baseline values of the following PFT
parameters correlated with higher serially measured FVC:
percentage predicted FVC (P < 0.001), percentage pre-
dicted forced expiratory volume in 1 second (P < 0.001),
percentage predicted DLco (P < 0.001), percentage total
lung capacity (P < 0.001) and the forced expiratory
volume in 1 second/FVC ratio <0.75 (P = 0.004).
As shown in Table 2, the presence of anti-RNA poly-
merase III, anti-fibrillarin and anti-U1-ribonucleoprotein
antibodies, the body mass index and other examined
demographic and clinical variables were not significantly
associated with percentage predicted FVC.
We also examined the relationship of subscales of the
Medsger Severity Index with percentage predicted FVC.
As shown in Table 3, higher scores (more severe) for
the skin (P = 0.037) and lung (P < 0.001) subscales were
associated with lower levels of the investigated outcome
variable, whereas the other subscales (general, peripheral
vascular, joint/tendon, gastrointestinal tract, heart and
kidney) showed no significant relationship to FVC.
In addition, the smoking status did not show a signifi-
cant relationship to FVC. Furthermore, none of the
above-mentioned associations changed after correction
for current smoking status. Similarly, the above-men-
tioned associations did not change after exclusion of
patients ever treated with cyclophosphamide (data not
shown).
Role of ethnicity in progression of restrictive lung disease
in systemic sclerosis
We have previously reported that African American
patients with SSc had a higher frequency of pulmonary
fibrosis and a lower percentage predicted FVC at the
baseline visit in the GENISOS cohort [18]. As demon-
strated in Table 2, this group of patients also had lower
percentage predicted FVC after inclusion of all FVC
measurements, whereas this outcome variable among
Hispanic patients did not differ from that for white
patients. In a multivariable model, percentage predicted
Table 1 Baseline demographic characteristics of patients
enrolled in the GENISOS cohort
Characteristic Baseline value




African American 54 (20.3%)
Other 10 (3.76%)
Female sex 221 (83.08%)
Current smoker 49 (18.42%)
Ever smoker 134 (50.38%)
Disease duration (years)
a 2.53 (± 1.63)
Limited skin involvement 110 (41.35%)
Autoantibodies
Antinuclear antibodies 254 (95.49%)
Anti-centromere antibodies 32 (12.03%)
Anti-topoisomerase antibodies 49 (18.42%)




Percentage predicted forced vital capacity
> 80% 132 (58.15%)
50 to 80% 81 (35.68%)
< 50% 14 (6.17%)
Data presented as mean (± standard deviation) or n (%).
aTime interval
between date of onset of first non-Raynaud’s phenomenon symptom and
enrollment.
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predicted FVC
Prognostic variable Main effect adjusted for follow-
up time
d
Interaction term of baseline FVC
within 3 years of follow-up
e
Interaction term between
baseline FVC and up to 11 years
of follow-up
e
b (95% CI) P value b (95% CI) P value b (95% CI) P value
Follow-up time (years) -0.96 (-1.31 to -0.61) < 0.001 NA NA NA NA
Age at enrollment (years) 0.12 (-0.09 to 0.33) 0.263 -0.01 (-0.07 to 0.07) 0.914 -0.01 (-0.04 to 0.02) 0.592
Ethnicity
White 0 0
African American -11.59 (-19 to -4.19) 0.002 0.87 (-1.5 to 3.24) 0.473 0.13(-0.87 to 1.13) 0.799
Hispanic -0.82 (-7.24 to 5.59) 0.802 0.36 (-1.9 to 2.6) 0.752 -0.54 (-1.45 to 0.37) 0.243
Other -10.79 (-25.42 to 3.83) 0.148 0.37 (-3.51 to 4.26) 0.851 -0.72 (-2.39 to 0.94) 0.395
Female sex 6.76 (-0.38 to 13.9) 0.063 -2.19 (-4.42 to 0.05) 0.055 -0.57 (-1.51 to 0.37) 0.233
Body mass index -0.03 (-0.53 to 0.47) 0.905 -0.11 (-0.26 to 0.03) 0.138 0.01 (-0.06 to 0.07) 0.789
Current smoker 4.89 (-2.1 to 11.88) 0.17 0.91 (-1.16 to 2.99) 0.388 0.08 (-0.8 to 0.95) 0.867
Ever smoker 1.95 (-3.6 to 7.5) 0.491 1.25 (-0.43 to 2.93) 0.146 0.05 (-0.67 to 0.76) 0.899
Education level 1.39 (-0.13 to 2.91) 0.073 0.09 (-0.25 to 0.43) 0.599 -0.01 (-0.19 to 0.19) 0.999
Income level 0.39 (-0.93 to 1.71) 0.563 0.14 (-0.29 to 0.57) 0.523 -0.03 (-0.2 to 0.14) 0.746
Disease duration
a -0.26 (-1.97 to 1.45) 0.767 0.03 (-0.49 to 0.54) 0.924 -0.01 (-0.23 to 0.21) 0.94
Disease duration (alternative method)
b 0.54 (0.04 to 1.04) 0.034 0.04 (-0.09 to 0.17) 0.582 -0.01 (-0.07 to 0.05) 0.753
Limited disease 7.08 (1.57 to 12.59) 0.012 -0.66 (-2.35 to 1.0.03) 0.442 0.03 (-0.68 to 0.74) 0.932
Autoantibodies
ANA -2.07 (-16.01 to 11.87) 0.771 0.46 (-3.34 to 4.27) 0.812 -1.07 (-2.74 to 0.61) 0.214
ACA 22.73 (14.82 to 30.65) < 0.001 -1.74 (-4.29 to 0.81) 0.182 -0.39 (-1.43 to 0.65) 0.463
ATA -12.49 (-19.44 to -5.53) < 0.001 -2.49 (-4.62 to -0.36) 0.022 -0.72 (-1.63 to 0.19) 0.121
Anti-RNA polymerase III -0.75 (-7.35 to 5.86) 0.824 0.22 (-1.69 to 2.13) 0.825 0.02 (-0.79 to 0.84) 0.955
Anti-U1-ribonucleoprotein -1.32 (-10.18 to 7.54) 0.771 0.47 (-2.96 to 3.9) 0.788 0.08 (-1.24 to 1.4) 0.901
Anti-Ro -1.83 (-18.42 to 14.75) 0.829 4.63 (-0.29 to 9.56) 0.065 0.89 (-1.16 to 2.94) 0.394
Anti-fibrillarin -3.42 (-12.26 to 5.41) 0.448 -0.49 (-3.58 to 2.58) 0.751 -0.06 (-1.35 to 1.22) 0.921
Modified RSS -0.41 (-0.65 to -0.17) 0.001 -0.95 (-2.37 to 0.47) 0.191 0.01 (-0.02 to 0.04) 0.43
VAS for dyspnea -1.98 (-2.86 to -1.1) < 0.001 0.21 (-0.1 to 0.52) 0.193 0.05 (-0.09 to 0.19) 0.471
VAS for pain -0.35 (-0.91 to 0.21) 0.221 0.07 (-0.07 to 0.22) 0.331 0.05 (-0.02 to 0.12) 0.184
Teleagiectasia
Facial/oral 2.78 (-2.76 to 8.31) 0.326 1.24 (-0.44 to 2.91) 0.148 0.35 (-0.35 to 1.05) 0.329
Palmar 1.34 (-4.65 to 7.33) 0.661 1.09 (-0.68 to 2.88) 0.225 0.51 (-0.22 to 1.25) 0.176
Dysphagia 1.39 (-4.14 to 6.93) 0.621 0.13 (-1.55 to 1.82) 0.879 0.3 (-0.41 to 1.01) 0.404
sPAP increase by echo 0.2 (-13.36 to 13.75) 0.977 3.51 (0.27 to 6.74) 0.033 0.16 (-0.40 to 3.51) 0.119
Auscultatory rales -16.64 (-22.92 to -10.36) < 0.001 0.45 (-1.49 to 2.39) 0.651 -0.32 (-1.17 to 0.54) 0.464
Fibrosis on CXR -26.67 (-33.07 to -20.27) < 0.001 1.09 (-1.35 to 3.54) 0.379 -0.8 (-1.85 to 0.25) 0.137
Baseline FVC%
c 0.94 (0.86 to 1.02) < 0.001 -0.01 (-0.07 to 0.06) 0.869 -0.02 (-0.4 to 0.01) 0.066
Baseline FEV1% 0.94 (0.87 to 1.01) < 0.001 0.01 (-0.07 to 0.08) 0.874 -0.01(-0.03 to 0.01) 0.222
Baseline DLco% 0.46 (0.36 to 0.57) < 0.001 -0.01 (-0.01 to 0.01) 0.387 0.01 (-0.01 to 0.02) 0.655
Baseline TLC% 0.82 (0.73 to 0.92) < 0.001 0.01 (-0.01 to 0.01) 0.175 -0.01 (-0.03 to 0.01) 0.389
FEV1/FVC <0.75 9.16 (2.88 to 15.45) 0.004 -1.52 (-5.98 to 2.94) 0.505 -0.21 (-0.98 to 0.56) 0.597
Creatinine ≥1.5 -6.91 (-24.89 to 11.07) 0.452 4.88 (-1.35 to 11.11) 0.125 -0.35 (-3.52 to 2.82) 0.828
CPK >200 -7.81 (-15.5 to -0.13) 0.046 2.1 (-0.26 to 4.47) 0.081 0.49 (-0.52 to 1.51) 0.337
Hematocrit -0.01 (-0.64 to 0.64) 0.999 -2.75 (-11.14 to 5.65) 0.521 -0.02 (-0.11 to 0.07) 0.685
White blood cells -0.91 (-1.89 to 0.06) 0.067 -0.01 (-0.01 to 0.01) 0.072 0.04 (-0.07 to 0.16) 0.465
Elevated platelet count -3.37 (-9.62 to 2.86) 0.289 0.08 (-1.64 to 1.8) 0.928 -0.22 (-1.03 to 0.59) 0.599
ACA, anti-centromere antibodies; ANA, anti-nuclear antibodies; ATA, anti-topoisomerase antibodies; b, regression coefficient; CI, confidence interval; CPK, creatine
phosphokinase; CXR, Chest X-ray; DLco, lung diffusion capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; RSS,
Rodnan Skin Score; sPAP, systolic pulmonary arterial pressure; TLC, total lung capacity; VAS, visual analog scale.
aDisease onset defined as first non-Raynaud’s
phenomenon symptom.
bDisease onset defined as first symptom attributable to SSc.
cBaseline FVC measurements were not included in the outcome variable for
this analysis.
dMain effect adjusted for follow-up time.
eInteraction term between the follow-up time and the respective baseline variable (outcome: rate of
decline in FVC). Bold data represent significant associations (P < 0.05).
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significantly lower than white patients even after adjust-
ment for disease duration, ATA and ACA positivity, dis-
ease type, and smoking status, in addition to income
and education levels (P = 0.038; regression coefficient
(RC) = -7.73, confidence interval (CI) = -15.02 to -0.45),
whereas Hispanic patients did not differ from white
patients (P = 0.733; RC = 1.21, CI = -5.33 to 7.58).
These results indicate that African American patients
had lower percentage predicted FVC independent of
smoking status, socioeconomic factors, disease duration/
type (limited versus diffuse cutaneous disease) and
serology.
Predictors of rate of decline in percentage predicted FVC
As shown in Figure 1, our data did not indicate that the
overall decline in percentage predicted FVC slowed
down during the follow-up time. This was also demon-
strated by the fact that the curvilinear model for pro-
gression of percentage predicted FVC did not show a
better fit to the data than the linear model. The fre-
quency of patients with ≥10% decline in percentage pre-
dicted FVC increased at a slower pace, however, from
16.7% in the first year of follow-up to 45.9% after ≥8
years of follow-up (Table 4).
We next investigated which baseline variables are pre-
dictors of accelerated decline in FVC. For this purpose,
the interaction term between the respective variable and
follow-up time was examined. As shown in Tables 2
and 3, presence of ATA was the only variable associated
with sequentially obtained FVC levels that also predicted
the rate of decline within the first 3 years of follow-up.
Presence of ATA was associated with a higher decline
rate in FVC in this time period (P = 0.022, RC = -2.49,
CI = -4.62 to -0.36). Presence of ATA was not a signifi-
cant predictor of FVC decline rate, however, when the
follow-up time was not restricted (P = 0.121). The latter
analysis included FVC measurements that were obtained
up to 11.4 years after enrollment.
The interaction term for elevated systolic pulmonary
arterial pressure on the echocardiogram was also signifi-
cant when the analysis was restricted to 3-year follow-
up. However, this variable was not associated with
sequentially obtained FVC levels (insignificant main
effect, P = 0.997). Furthermore, an echocardiogram was
obtained only in 23.7% of patients at enrollment.
Other baseline variables associated with differential
FVC levels did not predict progression of this variable
over time in 3-year or long-term follow-up analyses.
Specifically, ethnicity, autoantibody status, subjective
dyspnea, baseline PFT values, Medsger Severity Index
subscores and smoking status did not predict the rate of
progression in FVC.
Figure 2a,b shows graphically that the progression of
the outcome variable was not significantly different
among patients with limited versus diffuse disease types;
this was further supported by the fact that the interac-
tion term between disease type and follow-up time was
not significant (P = 0.442 for 3-year follow-up, P =
0.932 for long-term follow-up). Similarly, the interaction
term for disease duration at enrollment and follow-up
time also was not significant (P = 0.767 for 3-year fol-
low-up, P = 0.94 for long-term follow-up), indicating
that shorter disease duration did not predicted a signifi-
cantly faster rate of decline in FVC. To demonstrate this
observation graphically, SSc patients were divided into
two groups based on disease duration of 2 years. One
hundred and nineteen (44.7%) patients had disease dura-
tion <2 years at the initial visit. As indicated in Figure
2c,d, the slope of decline in the percentage predicted
FVC was not significantly different between these two
groups.
Similarly, the disease duration measured from the time
of first symptom attributable to SSc (see Table 2,
Table 3 Predictive significance of Severity Index subscales for progression of FVC
Medsger Severity Index Main effect adjusted for follow-
up time
Interaction term of baseline FVC
within 3 years of follow-up
Interaction term between baseline FVC
and up to 11 years of follow-up
b (95% CI) P value b (95% CI) P value b (95% CI) P value
General -0.22 (-3.65 to 3.19) 0.897 0.0 (-0.01 to 0.01) 0.463 0.01 (-0.48 to 0.5) 0.972
Peripheral vascular -0.81 (-3.31 to 1.69) 0.525 0.0 (-0.01 to 0.01) 0.436 0.1 (-0.21 to 0.41) 0.513
Skin -3.61 (-7 to -0.22) 0.037 0.58 (-2.41 to 1.24) 0.531 0.17 (-0.27 to 0.61) 0.449
Joint/tendon -2.14 (-4.48 to 0.19) 0.072 -0.19 (-1.15 to 0.75) 0.682 -0.06 (-0.37 to 0.25) 0.712
Muscle -5.61 (-12.22 to 1) 0.096 -0.32 (-1.27 to 0.63) 0.504 0.23 (-0.61 to 1.07) 0.588
Gastrointestinal tract -0.26 (-4.58 to 4.06) 0.905 0.0 (-0.01 to 0.01) 0.369 0.02 (-0.61 to 0.65) 0.955
Lung -9.73 (-11.91 to -7.55) < 0.001 0.0 (-0.01 to 0.01) 0.707 -0.29 (-0.62 to 0.03) 0.077
Heart -1.98 (-6.17 to 2.2) 0.353 0.0 (-0.01 to 0.01) 0.321 0.24 (-0.44 to 0.92) 0.493
Kidney 0.62 (-6.84 to 8.09) 0.87 0.0 (-0.01 to 0.01) 0.128 -0.22 (-1.64 to 1.19) 0.756
b, regression coefficient; CI, confidence interval; FVC, forced vital capacity. Bold data represent significant associations (P < 0.05).
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the rate of decline in the percentage predicted FVC (P =
0.582 for 3-year follow-up, P = 0.753 for long-term fol-
low-up.
Rate of FVC decline among deceased patients
Seventy-three patients (27.4%) died during follow-up. As
expected, the deceased patients had lower serial FVC
values (P = 0.001, RC = -10.08, CI = -16.26 to -3.89).
Furthermore, the examination of the interaction term
between follow-up time and vital status revealed that
the deceased patients had a significantly faster rate of
decline in percentage predicted FVC compared with the
remainder of the patients (P = 0.001, RC = -1.66, CI =
-2.63 to -0.69) for long-term follow-up).
Discussion
In the current study, we investigated the association and
predictive significance of baseline demographic and clin-
ical variables with sequentially obtained percentage
predicted FVC measurements in a large prospective
cohort of early SSc patients. Similar to our previous
cross-sectional study [18], a number of baseline charac-
teristics were associated with FVC levels. Only ATA,
however, was associated with lower serial FVC levels as
well as with a higher decline rate in FVC at 3-year
follow-up.
Our results confirm the previously reported associa-
tion of ACA [11-13,13-15,34] and ATA with FVC levels;
that is, those patients with ACA have higher percentage
predicted FVC, and those patients with ATA have lower
percentage predicted FVC. Previous reports also have
indicated that patients with anti-RNA polymerase III
antibodies have extensive skin involvement but less fre-
quent ILD [13,35]. These antibodies, however, were not
associated with higher percentage predicted FVC levels
in our study. Presence of ATA was also a predictor of
an accelerated decline rate in FVC within 3 years of
enrollment; however, presence of ATA was not a signifi-
cant predictor of the FVC decline rate on long-term
Figure 1 Course of percentage predicted forced vital capacity over 2-year intervals of follow-up. Percentage predicted forced vital
capacity (FVC%) data presented in box-and-whisker plots. Each box represents the 25th to 75th percentile: length of box represents interquartile
range (IQR); line inside represents median. Whiskers represent 1.5 times the upper and lower IQRs. Circles indicate outliers. *Number of patients
who had at least one FVC measurement during the follow-up interval.
Table 4 Frequency of 5% or 10% decline in percentage predicted FVC during the follow-up period
Frequency of decline in baseline FVC Follow-up year
1234567> 8
≥5% 31.2 36.4 41.0 49.3 47.9 52.5 46.2 51.4
≥10% 16.7 18.2 23.1 31.0 32.9 30.5 38.5 45.9
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Page 7 of 11follow-up (up to 11.5 years). This discrepancy can be
partially explained by the fact that patients with rapidly
progressive ILD had higher mortality and were not well
represented in the long-term follow-up group.
The GENISOS cohort includes a considerable number
of Hispanic patients (n = 77) and African American
patients (n = 54), raising the possibility that our findings
also are generalizable to nonwhite patient populations.
In our study, African American patients had lower levels
of percentage predicted FVC, even after adjusting for
socioeconomic factors, antibody status and smoking
habits. This observation might partially explain lower
survival of nonwhite patients in the GENISOS cohort
[36] and in other studies [37-39]. However, our results
confirmed that African American ethnicity per se does
not predict the rate of decline in percentage predicted
FVC [7,20].
One study reported that SSc patients who were former
smokers had an accelerated rate of decline in FVC [19],
but this finding has not been confirmed by other studies
[7,14,20,22]. We did not observe an association between
smoking and percentage predicted FVC levels or its rate
of decline. It is possible that smoking status influences
progression of other PFT parameters such as the total
lung capacity and DLco.
Two retrospective studies indicated that low baseline
FVC levels predicted accelerated rate of decline in this
variable over time [16,22]. Both studies conducted a
time to decline analysis rather than directly measuring
the decline rate in FVC. Other studies, using an annual-
ized rate of decline to measure percentage predicted
FVC, reported no association between baseline FVC and
the annualized rate of decline [7,14,21]. Similarly, our
study did not indicate that low baseline PFT parameters
predicted a higher rate of decline in FVC on subsequent
visits.
Some studies have indicated that the loss of volume
on PFTs was greatest early in the course of disease and
that the rate of decline in percentage predicted FVC
decelerates over time [7,8,20], while others could not
confirm this finding [9]. Disease onset was defined as
the time of first symptom attributable to SSc in the first
two studies [7,14]. In our study, the overall rate of
decline in percentage predicted FVC did not slow down
during the follow-up time; similar results were seen in
our subgroup analyses according to disease type and
duration. We used the two most commonly adopted
methods for calculation of disease duration in our study.
The disease duration determined by both calculation
methods was not a significant predictor of rate of
decline in FVC. Similar to our findings, the rate of
decline in FVC did not differ significantly in the Sclero-
derma Lung Study when patients were stratified accord-
ing to disease duration [40]. The frequency of patients
with ≥10% decline in FVC, however, showed its highest
increase in the first follow-up year and increased only at
a slower pace to 45.9% after ≥8y e a r so ff o l l o w - u pi n
our study (Table 4). This raises the possibility that a
Figure 2 Progression of percentage predicted forced vital capacity. Percentage predicted forced vital capacity (FVC%) progression in (a)
patients with limited cutaneous involvement, (b) patients with diffuse cutaneous involvement, (c) patients with disease duration at enrollment
<2 years, and (d) patients with disease duration at enrollment >2 years. Data are shown as box-and-whisker plots; for more details, see Figure 1.
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Page 8 of 11smaller subgroup of patients has an accelerated decline
rate in the initial phase of disease. The FVC decline in
these patients might stabilize in later follow-up years if
they survive the initial rapid worsening of the ILD.
However, this subgroup might not be well represented
in patients with longer follow-up time because of its
higher mortality rate.
We utilized a random-effect repeated-measurement
model for our analyses. This approach utilizes all fol-
low-up FVC measurements and accounts for the within-
subject correlation. The approach therefore provides
more accurate estimation of predictors for rate of
decline than the time to decline or the annualized rate
of decline analysis methods utilized in previous studies
[7,14,16,17,19-21,23].
Confirming findings of a previous study [21], we
observed that a faster rate of decline in percentage pre-
dicted FVC was a marker of poor survival. This finding
emphasizes the importance of predictive parameters for
progression of FVC. However, our findings also support
the results of previous studies [7,14,20,21,23] in which
routinely obtained demographic and clinical parameters -
except for ATA - failed to predict the rate of decline in
FVC over time.
Consequently, our study provides further support for
the identification of predictive biomarkers utilizing
novel imagining and molecular techniques. Two pre-
vious reports indicated that the extent of reticular pat-
tern on high-resolution computed tomography (HRCT)
utilizing a semiquantitative scoring system predicts
further decline in FVC [22,41]. The fibrosis score based
on HRCT was not captured in our study and is not yet
available for routine clinical use, but has promise for
future studies. Another study has indicated that high
sedimentation rates at baseline predict a faster decline
in percentage predicted FVC [14]. Furthermore, SSc
patients with ILD had more severe reflux disease on
monometry and impedance PH monitoring in a cross-
sectional study [42]. The severity of esophageal involve-
ment on monometry, however, was not predictive of the
decline in FVC in a prospective study [17].
Furthermore, a polymorphism in the IRF5 gene was
associated with ILD in a cross-sectional sample of SSc
patients [43]. Others have reported that pneumoproteins
such as surfactant protein D and Krebs von den Lungen-
6 correlate with the presence of pulmonary fibrosis and
alveolitis in SSc [44,45]. However, large observational
cohort studies with a collection of genetic data and serial
blood samples are needed to investigate the predictive
significance of these potentially useful biomarkers.
Cyclophosphamide is the only treatment for ILD that
has been demonstrated to be effective in SSc [41,46].
Considering that only a small portion of our patients
were ever treated with cyclophophamide (8.27%), we
b e l i e v eo u ro b s e r v a t i o n sa r ec l o s et ot h en a t u r a lh i s t o r y
of ILD in SSc. Furthermore, a subgroup analysis after
exclusion of patients ever treated with cyclophospha-
mide did not change our overall results. We cannot,
however, exclude that treatment with various potentially
effective medications may have influenced our findings.
Another limitation of the current study is that the
majority of investigated patients did not undergo HRCT
at enrollment, and therefore the predictive significance
of the previously described semiquantitative scoring sys-
tem on HRCT could not be investigated in our cohort
[22,41]. Furthermore, most of our patients were
recruited from tertiary-care rheumatology clinics in
South Texas, raising the possibility of a referral bias
toward more severe disease.
Despite the present study’s prospective design and
relatively large sample size, we cannot exclude the possi-
b i l i t yt h a tw ea r es t i l lu n d e r p o w e r e dt oi d e n t i f ym o r e
subtle clinical and demographic predictors of decline in
percentage predicted FVC. Furthermore, it is possible
that some of the observed associations are false-positive
findings; we did not correct for multiple comparisons in
order to decrease the likelihood of missing clinically
important associations (b-error).
Conclusions
Our results support a continuous loss of pulmonary vital
capacity that persists into the later course of SSc. A
number of baseline variables were associated with seri-
ally measured levels of percentage predicted FVC. Pre-
sence of ATA was the only variable associated with
serial FVC measurements that also predicted the rate of
decline in FVC within the first 3 years of follow-up.
None of the above-mentioned variables, however, pre-
dicted the decline rate in vital capacity upon longer fol-
low-up time (up to 11.4 years). A faster rate of decline
in percentage predicted FVC was associated with poor
survival, emphasizing the need for identification of pre-
dictive biomarkers. Large observational studies with col-
lection of genetic data and serial blood samples are an
important asset for identification of new predictors.
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